Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Apr 16, 2024 8:10pm
152 Views
Post# 35992794

RE:RE:RE:RE:Have a think!!

RE:RE:RE:RE:Have a think!! Like I said, the wording of the ballot is a red herring.
The only measure of Onc success is getting Pela to market.
That outcome is 100% based on ongoing trials. All controlled by 3rd party agencies.
also with lots of guakongside Roche.
I have not validated, but willing to bet the wording of ballets is governed by outseide directives.
100% guaranteed vetted by lawyers & accountants.
You might ask the auditor agency why the choice of words.
All public traded companies have to follow regulatory guidelines.
closing as I started who cares!
other point. The results are reported, as a % of votes. Not a a % of available votes.
democracy?
don't vote, it is neither a negative or positive.
please at least know what you are talking about, before posting an argument.
last week Onc applied for a phase 3 enrolment meeting with the FDA.
that is important & valuable information.


<< Previous
Bullboard Posts
Next >>